Elacestrant

Drug Profile

Elacestrant

Alternative Names: RAD-1901

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Developer Radius Health Inc.
  • Class Osteoporosis therapies; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Selective estrogen receptor degraders; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Vasomotor symptoms
  • Phase I Breast cancer

Most Recent Events

  • 21 Apr 2017 Chemical structure information added
  • 24 Mar 2017 Radius health has composition of matter patents pending for RAD 1901 in India and dosage form patents pending in USA, Canada and Mexico (Radius Health's form 10-K, filed in February 2017).
  • 24 Feb 2017 Radius health has patent protection for RAD 1901 in USA, Australia, Canada, Japan, Poland, and Europe (Radius Health's form 10-K, filed in February 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top